New York State Common Retirement Fund Has $4.60 Million Stock Holdings in Emergent Biosolutions Inc. $EBS

New York State Common Retirement Fund lifted its stake in shares of Emergent Biosolutions Inc. (NYSE:EBS) by 32.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 522,004 shares of the biopharmaceutical company’s stock after acquiring an additional 128,429 shares during the quarter. New York State Common Retirement Fund owned approximately 0.98% of Emergent Biosolutions worth $4,604,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Legal & General Group Plc acquired a new position in shares of Emergent Biosolutions in the 2nd quarter worth approximately $31,000. Ameritas Investment Partners Inc. acquired a new position in Emergent Biosolutions in the second quarter valued at $35,000. Raymond James Financial Inc. bought a new stake in Emergent Biosolutions during the second quarter valued at $53,000. Janney Montgomery Scott LLC bought a new stake in Emergent Biosolutions during the second quarter valued at $68,000. Finally, ProShare Advisors LLC bought a new position in shares of Emergent Biosolutions in the 2nd quarter worth about $71,000. Institutional investors and hedge funds own 78.40% of the company’s stock.

Insider Activity at Emergent Biosolutions

In related news, Director Ronald Richard sold 21,984 shares of the company’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $11.97, for a total value of $263,148.48. Following the sale, the director owned 98,417 shares in the company, valued at $1,178,051.49. This represents a 18.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.20% of the stock is currently owned by insiders.

Emergent Biosolutions Price Performance

Shares of EBS opened at $10.93 on Friday. The business’s fifty day moving average is $11.99 and its 200 day moving average is $10.00. Emergent Biosolutions Inc. has a 12-month low of $4.02 and a 12-month high of $14.06. The company has a quick ratio of 3.15, a current ratio of 5.76 and a debt-to-equity ratio of 1.14. The stock has a market cap of $574.04 million, a P/E ratio of 8.41 and a beta of 2.35.

Wall Street Analysts Forecast Growth

EBS has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Emergent Biosolutions in a research report on Tuesday, December 16th. Weiss Ratings restated a “hold (c-)” rating on shares of Emergent Biosolutions in a report on Monday, December 29th. Wall Street Zen raised shares of Emergent Biosolutions from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 30th. Finally, Zacks Research upgraded shares of Emergent Biosolutions to a “hold” rating in a research report on Friday, October 24th. One investment analyst has rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $15.00.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.